Fzd2 has, therefore, been studied as a therapeutic target reducing metastases in xenograft mouse models of CRC [45]; however, further research is required to understand the role of Fzd2 and to develop it as a therapeutic target. The gene discussed is FZD2; the disease is colorectal carcinoma.